Pharmacokinetics, Safety, and Dosing of Novel Pediatric Levofloxacin Dispersible Tablets in Children with Multidrug-Resistant Tuberculosis Exposure | Zendy

Anthony J. GarciaPrats | Zendy; Susan E. Purchase | Zendy; Muhammad Osman | Zendy; Heather R. Draper | Zendy; H. Simon Schaaf | Zendy; Lubbe Wiesner | Zendy; Paolo Denti | Zendy; Anneke C. Hesseling | Zendy

Open Access

Pharmacokinetics, Safety, and Dosing of Novel Pediatric Levofloxacin Dispersible Tablets in Children with Multidrug-Resistant Tuberculosis Exposure

Author(s) -

Anthony J. GarciaPrats,

Susan E. Purchase,

Muhammad Osman,

Heather R. Draper,

H. Simon Schaaf,

Lubbe Wiesner,

Paolo Denti,

Anneke C. Hesseling

Publication year - 2019

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01865-18

Subject(s) - levofloxacin , pharmacokinetics , dosing , medicine , bioavailability , pharmacology , tuberculosis , antibiotics , chemistry , pathology , biochemistry

This study characterized the pharmacokinetics of novel 100-mg levofloxacin dispersible tablets in 24 children aged <5 years who had household multidrug-resistant tuberculosus (MDR-TB) exposure. The current data were pooled with previously published data from children (n = 109) with MDR-TB receiving adult (250-mg) levofloxacin tablets, using nonlinear mixed-effects modelling.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research